186 related articles for article (PubMed ID: 29039719)
1. Resistance in In Vitro Selected Tigecycline-Resistant Methicillin-Resistant Staphylococcus aureus Sequence Type 5 Is Driven by Mutations in mepR and mepA Genes.
Dabul ANG; Avaca-Crusca JS; Van Tyne D; Gilmore MS; Camargo ILBC
Microb Drug Resist; 2018 Jun; 24(5):519-526. PubMed ID: 29039719
[TBL] [Abstract][Full Text] [Related]
2. Mutations in the MepRAB efflux system contribute to the in vitro development of tigecycline resistance in Staphylococcus aureus.
Fang R; Sun Y; Dai W; Zheng X; Tian X; Zhang X; Wang C; Cao J; Zhou T
J Glob Antimicrob Resist; 2020 Sep; 22():631-636. PubMed ID: 32590185
[TBL] [Abstract][Full Text] [Related]
3. Genetic changes associated with tigecycline resistance in Staphylococcus aureus in vitro-selected mutants belonging to different lineages.
Herrera M; Gregorio SD; Haim MS; Posse G; Mollerach M; Di Conza J
Int J Antimicrob Agents; 2021 Apr; 57(4):106304. PubMed ID: 33588015
[TBL] [Abstract][Full Text] [Related]
4. Tigecycline Resistance-Associated Mutations in the MepA Efflux Pump in Staphylococcus aureus.
Huang H; Wan P; Luo X; Lu Y; Li X; Xiong W; Zeng Z
Microbiol Spectr; 2023 Aug; 11(4):e0063423. PubMed ID: 37432114
[TBL] [Abstract][Full Text] [Related]
5. A novel MATE family efflux pump contributes to the reduced susceptibility of laboratory-derived Staphylococcus aureus mutants to tigecycline.
McAleese F; Petersen P; Ruzin A; Dunman PM; Murphy E; Projan SJ; Bradford PA
Antimicrob Agents Chemother; 2005 May; 49(5):1865-71. PubMed ID: 15855508
[TBL] [Abstract][Full Text] [Related]
6. First description of rpsJ and mepA mutations associated with tigecycline resistance in Staphylococcus aureus isolated from a cystic fibrosis patient during antibiotic therapy.
Haim MS; Di Gregorio S; Galanternik L; Lubovich S; Vázquez M; Bharat A; Zaheer R; Golding GR; Graham M; Van Domselaar G; Cardona ST; Mollerach M
Int J Antimicrob Agents; 2017 Dec; 50(6):739-741. PubMed ID: 29038088
[No Abstract] [Full Text] [Related]
7. Mutations at the Ribosomal S10 Gene in Clinical Strains of Staphylococcus aureus with Reduced Susceptibility to Tigecycline.
Argudín MA; Roisin S; Dodémont M; Nonhoff C; Deplano A; Denis O
Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29084741
[TBL] [Abstract][Full Text] [Related]
8. The molecular mechanisms of allosteric mutations impairing MepR repressor function in multidrug-resistant strains of Staphylococcus aureus.
Birukou I; Tonthat NK; Seo SM; Schindler BD; Kaatz GW; Brennan RG
mBio; 2013 Aug; 4(5):e00528-13. PubMed ID: 23982071
[TBL] [Abstract][Full Text] [Related]
9. In vitro activity of tigecycline against methicillin-resistant Staphylococcus aureus, including livestock-associated strains.
Verkade EJ; Verhulst CJ; Huijsdens XW; Kluytmans JA
Eur J Clin Microbiol Infect Dis; 2010 May; 29(5):503-7. PubMed ID: 20186450
[TBL] [Abstract][Full Text] [Related]
10. [In vitro activity of tigecycline against methicillin-resistant staphylococci].
Tunçkanat F; Saribaş Z; Ercis S
Mikrobiyol Bul; 2009 Apr; 43(2):211-5. PubMed ID: 19621605
[TBL] [Abstract][Full Text] [Related]
11. Functional consequences of substitution mutations in MepR, a repressor of the Staphylococcus aureus MepA multidrug efflux pump gene.
Schindler BD; Seo SM; Jacinto PL; Kumaraswami M; Birukou I; Brennan RG; Kaatz GW
J Bacteriol; 2013 Aug; 195(16):3651-62. PubMed ID: 23749979
[TBL] [Abstract][Full Text] [Related]
12. Activity of tigecycline against methicillin-resistant Staphylococcus aureus (MRSA) from respiratory tract sources.
Hawser SP
Int J Antimicrob Agents; 2010 Apr; 35(4):414-5. PubMed ID: 20137900
[No Abstract] [Full Text] [Related]
13. Activity of tedizolid (TR-700) against well-characterized methicillin-resistant Staphylococcus aureus strains of diverse epidemiological origins.
Thomson KS; Goering RV
Antimicrob Agents Chemother; 2013 Jun; 57(6):2892-5. PubMed ID: 23571550
[TBL] [Abstract][Full Text] [Related]
14. Association of mprF mutations with cross-resistance to daptomycin and vancomycin in methicillin-resistant Staphylococcus aureus (MRSA).
Thitiananpakorn K; Aiba Y; Tan XE; Watanabe S; Kiga K; Sato'o Y; Boonsiri T; Li FY; Sasahara T; Taki Y; Azam AH; Zhang Y; Cui L
Sci Rep; 2020 Sep; 10(1):16107. PubMed ID: 32999359
[TBL] [Abstract][Full Text] [Related]
15. Frequency of efflux pump genes mediating ciprofloxacin and antiseptic resistance in methicillin-resistant Staphylococcus aureus isolates.
Hassanzadeh S; Mashhadi R; Yousefi M; Askari E; Saniei M; Pourmand MR
Microb Pathog; 2017 Oct; 111():71-74. PubMed ID: 28826767
[TBL] [Abstract][Full Text] [Related]
16. [Comparison of tigecycline and vancomycin activities in an in vitro biofilm model generated with methicillin-resistant Staphylococcus aureus].
Aslan H; Yapar N
Mikrobiyol Bul; 2015 Oct; 49(4):475-83. PubMed ID: 26649405
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of tigecycline alone and with rifampin in foreign-body infection by methicillin-resistant Staphylococcus aureus.
Garrigós C; Murillo O; Euba G; Verdaguer R; Tubau F; Cabellos C; Cabo J; Ariza J
J Infect; 2011 Sep; 63(3):229-35. PubMed ID: 21763722
[TBL] [Abstract][Full Text] [Related]
18. Tigecycline induction of phenol-soluble modulins by invasive methicillin-resistant Staphylococcus aureus strains.
Yamaki J; Synold T; Wong-Beringer A
Antimicrob Agents Chemother; 2013 Sep; 57(9):4562-5. PubMed ID: 23817369
[TBL] [Abstract][Full Text] [Related]
19. Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model.
Crandon JL; Banevicius MA; Nicolau DP
Antimicrob Agents Chemother; 2009 Mar; 53(3):1165-9. PubMed ID: 19114676
[TBL] [Abstract][Full Text] [Related]
20. The In Vitro Evaluation of Tigecycline and the In Vivo Evaluation of RPX-978 (0.5% Tigecycline) as an Ocular Antibiotic.
Romanowski EG; Kowalski TA; O'Connor KE; Yates KA; Mah FS; Shanks RM; Kowalski RP
J Ocul Pharmacol Ther; 2016 Mar; 32(2):119-26. PubMed ID: 26545167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
